Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q8N1G2
UPID:
CMTR1_HUMAN
Alternative names:
Cap methyltransferase 1; Cap1 2'O-ribose methyltransferase 1; FtsJ methyltransferase domain-containing protein 2; Interferon-stimulated gene 95 kDa protein
Alternative UPACC:
Q8N1G2; A8K949; Q14670; Q96FJ9
Background:
Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 1, also known as Cap methyltransferase 1, plays a crucial role in mRNA processing by mediating mRNA cap1 2'-O-ribose methylation. This modification enhances mRNA stability and translation efficiency, indicating its pivotal role in gene expression regulation. The enzyme prefers cap0 transcripts, highlighting its specificity in cellular mRNA metabolism.
Therapeutic significance:
Understanding the role of Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 1 could open doors to potential therapeutic strategies. Its involvement in the interferon response pathway suggests a possible link to immune response modulation, offering a promising avenue for research into treatments for diseases with an immune component.